Trial reportCritical care (London, England)2010
The use of exenatide in severely burned pediatric patients.
Trial report in Critical care (London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of Mechanisms of Improved Wound Healing of Anabolic Agents and Diet in Severely Burned Patients
Phase 1-2 Study of the Pharmacology of Exenatide in Pediatric Sepsis
Who cites it
22 citing papers in PubMed, 45 citations in OpenAlex.
- Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes.Critical care (London, England) · 2011Trial
- Endocrine disruptions in thermal injuries: exploring immune system interactions.Physiological reviews · 2026Review
- Beyond diabetes: harnessing the power of metformin in burn care.Critical care (London, England) · 2025Review
- Glucose Metabolism in Burns-What Happens?International journal of molecular sciences · 2021Review
- Current problems in burn hypermetabolism.Current problems in surgery · 2020Review
- Debate on Insulin vs Non-insulin Use in the Hospital Setting-Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?Current diabetes reports · 2019Review
- Exendin-4 Exacerbates Burn-Induced Morbidity in Mice by Activation of the Sympathetic Nervous System.Mediators of inflammation · 2019Article
- Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting.Current diabetes reports · 2017Review
- Update on Glucose Management Among Noncritically Ill Patients Hospitalized on Medical and Surgical Wards.Journal of the Endocrine Society · 2017Review
- Management of hospitalized type 2 diabetes mellitus patients.Journal of translational internal medicine · 2016Article
- The metabolic stress response to burn trauma: current understanding and therapies.Lancet (London, England) · 2016Review
- The potential role of incretin therapy in the hospital setting.Clinical diabetes and endocrinology · 2015Article
- Burns in children: standard and new treatments.Lancet (London, England) · 2014Review
- The use of non-insulin anti-diabetic agents to improve glycemia without hypoglycemia in the hospital setting: focus on incretins.Current diabetes reports · 2014Review
- Clinical review: Glucose control in severely burned patients - current best practice.Critical care (London, England) · 2013Review
- Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: Insulin therapy has proven itself and is considered the mainstay of treatment.Diabetes care · 2013Article
- Glycemic variability: Clinical implications.Indian journal of endocrinology and metabolism · 2013Article
- Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists!Diabetes care · 2013Article
- Burns: an update on current pharmacotherapy.Expert opinion on pharmacotherapy · 2012Review
- Burns: where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?Current opinion in clinical nutrition and metabolic care · 2011Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
introductionIntensive insulin treatment (IIT) has been shown to improve outcomes post-burn in severely burnt patients. However, it increases the incidence of hypoglycemia and is associated with risks and complications. We hypothesized that exenatide would decrease plasma glucose levels post-burn to levels similar to those achieved with IIT, and reduce the amount of exogenous insulin administered.
methodsThis open-label study included 24 severely burned pediatric patients. Six were randomized to receive exenatide, and 18 received IIT during acute hospitalization (block randomization). Exenatide and insulin were administered to maintain glucose levels between 80 and 140 mg/dl. We determined 6 AM, daily average, maximum and minimum glucose levels. Variability was determined using mean amplitude of glucose excursions (MAGE) and percentage of coefficient of variability. The amount of administered insulin was compared in both groups.
resultsGlucose values and variability were similar in both groups: Daily average was 130 ± 28 mg/dl in the intervention group and 138 ± 25 mg/dl in the control group (P = 0.31), MAGE 41 ± 6 vs. 45 ± 12 (respectively). However, administered insulin was significantly lower in the exenatide group than in the IIT group: 22 ± 14 IU patients/day in the intervention group and 76 ± 11 IU patients/day in the control group (P = 0.01). The incidence rate of hypoglycemia was similar in both groups (0.38 events/patient-month).
conclusionsPatients receiving exenatide received significantly lower amounts of exogenous insulin to control plasma glucose levels. Exenatide was well tolerated and potentially represents a novel agent to attenuate hyperglycemia in the critical care setting.
trial registrationNCT00673309.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.